Multiple Sclerosis Neurology
Indication definition, disease heterogeneity, symptom endpoints, DMT context, and clinical relevance.
Scientific advisory seatOpen institutional roles
Advisory Board &
Leadership Opportunities
Independent expertise to challenge the science, protect participants, and shape the company’s development architecture.
Priority expertise
Seats built around unresolved risk.
The initial board is organized by the questions that must be answered before either program can credibly advance.
MDMA Pharmacology
Dose rationale, pharmacokinetics, cardiovascular and psychiatric safety, interactions, and abuse potential.
Scientific advisory seatAcetaminophen Safety
Hepatic risk, cumulative exposure, pain rationale, combination design, and participant instructions.
Clinical safety seatBiostatistics & Trial Design
Four-arm component study, estimands, sample size, missing data, multiplicity, and reporting.
Methods advisory seatResearch Ethics
Belcopa disclosure boundary, consent, debriefing, vulnerability, trust, and independent oversight.
Ethics advisory seatRegulatory & CMC
Pre-IND sequence, controlled-substance requirements, GMP, formulation, analytical, and quality strategy.
Development advisory seatExpected commitment
Advice with a visible record.
- ✓Quarterly scientific reviewWritten critique of evidence, program assumptions, and development decisions.
- ✓Conflict disclosureFinancial, research, authorship, advocacy, and institutional interests.
- ✓Documented dissentMaterial disagreement is retained rather than edited into artificial consensus.
- ✓Participant protectionSafety and autonomy take priority over schedule, narrative, or sunk cost.
Express Interest
Submit professional background, expertise, conflicts, and the program questions you are prepared to examine.
Advisory participation does not imply endorsement of Belcopa, NovusClarus, the underlying manuscript, or any future trial. Independent criticism is a core function of the board.